Novel Antineoplastic Inducers of Mitochondrial Apoptosis in Human Cancer Cells

Area of Science:

• Oncology
• Pharmacology
• Biochemistry

Background:

• The Warburg effect describes cancer cells' reliance on glycolysis over mitochondrial respiration.
• Dysfunctional mitochondrial respiration and altered glucose metabolism are hallmarks of human cancers.
• Targeting these metabolic vulnerabilities presents a promising avenue for cancer therapy.

Purpose of the Study:

• To introduce two novel polyammonium cation drug compounds, P(op)T162 (compound 1) and PT167 (compound 3), for cancer suppression.
• To evaluate the in vitro efficacy of these compounds against a broad spectrum of human cancer cell lines.
• To elucidate the mechanism of action, including effects on apoptosis and cell cycle regulation.

Main Methods:

• Synthesis and characterization of novel polyammonium cation compounds (1, 2, and 3).
• In vitro testing of compounds 1 and 3 against the National Cancer Institute's 60-cancer cell line panel.
• Assessment of cellular effects, including apoptosis induction (cytochrome c release) and cell cycle modulation (p53, cyclin D1, p21 activation).

Main Results:

• Compounds 1 (P(op)T162) and 3 (PT167) demonstrated significant anti-cancer activity across all 60 tested human cancer cell lines.
• Both compounds exhibited cancerostatic (growth inhibition) and tumoricidal (cell death) effects, achieving near -100% cancer cell reduction.
• Mechanism involves inducing mitochondrial apoptosis via cytochrome c release and reactivating p53, leading to cell cycle arrest through p21 induction.

Conclusions:

• Novel polyammonium cations P(op)T162 and PT167 show potent in vitro anti-cancer efficacy.
• These compounds effectively target the Warburg effect and induce apoptosis in diverse human cancer types.
• The drugs represent a promising new strategy for complete cancer suppression by restoring p53 function and halting cell proliferation.